Potassium-transporting ATPase · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Potassium-transporting ATPase shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block. 13 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P20648. Start with gastroesophageal reflux disease, then reuse UniProt P20648 as the stable protein anchor across project notes and exports.
Start with gastroesophageal reflux disease, then reuse UniProt P20648 as the stable protein anchor across project notes and exports.
Potassium-transporting ATPase shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block. 13 linked drugs remain visible in the same block.
Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include ABEPRAZAN, DEXLANSOPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyPotassium-transporting ATPase alpha chain 1
Review this target as Potassium-transporting ATPase, mapped to UniProt P20648. ChEMBL maps the protein component as Potassium-transporting ATPase alpha chain 1. Sequence length is 1035 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Potassium-transporting ATPase as ChEMBL target CHEMBL2095173, mapped to UniProt P20648. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Potassium-transporting ATPase is the right protein anchor across sources, using UniProt P20648 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why gastroesophageal reflux disease is currently framed as approved-linked support. It currently carries 13 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Potassium-transporting ATPase |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | P20648 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Potassium-transporting ATPase alpha chain 1 |
| UniProt Accession | P20648 |
| Component Type | Protein |
| Sequence Length | 1035 aa |
Potassium-transporting ATPase alpha chain 1
Review this target as Potassium-transporting ATPase, mapped to UniProt P20648. ChEMBL maps the protein component as Potassium-transporting ATPase alpha chain 1. Sequence length is 1035 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Potassium-transporting ATPase shows approved-linked disease relevance led by gastroesophageal reflux disease. 5 more disease programs remain visible in the same review block.
Start review with gastroesophageal reflux disease because it currently carries approved-linked support. Linked drugs include ABEPRAZAN, DEXLANSOPRAZOLE, ESOMEPRAZOLE MAGNESIUM, ESOMEPRAZOLE SODIUM. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL1202672 | 7.7 | IC50 | 20.0 | Preclinical |
| CHEMBL1202661 | 7.52 | IC50 | 30.0 | Preclinical |
| CHEMBL1790041 | 7.4 | IC50 | 40.0 | Approved |
| CHEMBL1202621 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL1202647 | 7.3 | IC50 | 50.0 | Preclinical |
| CHEMBL47529 | 7.19 | IC50 | 65.0 | Preclinical |
| CHEMBL296482 | 7.19 | IC50 | 64.0 | Preclinical |
| CHEMBL1202681 | 7.1 | IC50 | 80.0 | Preclinical |
| CHEMBL1202667 | 7.05 | IC50 | 90.0 | Preclinical |
| CHEMBL1202658 | 6.96 | IC50 | 110.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| tissue-based format | 7 | 55 | 5.5 |
| protein complex format | 5 | 126 | 5.3 |
| organism-based format | 1 | 4 | 6.0 |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| assay format | 4 | 68 | 6.4 |